[Call to action] HIV prevention advocates applaud South Africa’s introduction of lenacapavir for PrEP

Call on donors and governments to accelerate access to deliver actual impact.

June 5, 2026 — In a landmark moment, South Africa today became the 9th African country to introduce lencapavir (LEN) for HIV prevention. South Africa’s introduction of LEN is especially significant given the country’s central role in shaping the regional HIV response and the global PrEP market. As the largest PrEP market in the world, South Africa’s leadership can help drive the demand, volume, market confidence and lower prices needed to accelerate equitable access across the continent and the world. HIV prevention partners AVAC, Advocates for the Prevention of HIV in Africa (APHA), and Access Bridge welcomed today’s news of increased commitments and support from the Global Fund, while calling for further ensure access is realized and impact achieved.

Read the full call to action here.

SEE ALSO:

• WHO applauds South Africa’s leadership in advancing HIV prevention through lenacapavir rollout
• African Alliance: South Africa helped create lenacapavir, Gilead should not decide who gets it
• The Conversation: HIV in South Africa: Why rolling out a groundbreaking new shot will miss a critical group of men
• Spotlight: All you need to know about the jab that could dramatically reduce new HIV infections in South Africa